Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide.
暂无分享,去创建一个
C. Catapano | G. Carbone | Carlo V Catapano | Giuseppina M Carbone | Eileen M McGuffie | Angela Collier | E. McGuffie | Angela Collier
[1] J. Black,et al. Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.
[2] Michael C. Ostrowski,et al. Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1 , 1997, Molecular and cellular biology.
[3] C. Catapano,et al. Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene. , 2000, Biochemistry.
[4] H. Krutzsch,et al. Cellular Nucleic Acid Binding Protein Regulates the CT Element of the Human c- myc Protooncogene (*) , 1995, The Journal of Biological Chemistry.
[5] S. Ross,et al. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[6] M. Roussel,et al. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. , 1994, Oncogene.
[7] H. Frierson,et al. Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.
[8] P. Pečinka,et al. DNA tetraplex formation in the control region of c-myc. , 1998, Nucleic acids research.
[9] V. Sementchenko,et al. ETS2 function is required to maintain the transformed state of human prostate cancer cells , 1998, Oncogene.
[10] P. Bates,et al. Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding* , 1999, The Journal of Biological Chemistry.
[11] F. Quadrifoglio,et al. Human cancer cell lines growth inhibition by GTn oligodeoxyribonucleotides recognizing single-stranded DNA-binding proteins. , 1998, European journal of biochemistry.
[12] V. Sementchenko,et al. Ets target genes: past, present and future , 2000, Oncogene.
[13] C. F. Bennett,et al. Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.
[14] R. Cardiff,et al. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. , 1999, Cancer research.
[15] C. Catapano,et al. Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene. , 2002, Nucleic acids research.
[16] P. Hanawalt,et al. Triple helix-forming oligonucleotides target psoralen adducts to specific chromosomal sequences in human cells. , 1999, Nucleic acids research.
[17] H. G. Kim,et al. Inhibition of transcription of the human c-myc protooncogene by intermolecular triplex. , 1998, Biochemistry.
[18] G. Viglietto,et al. Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. , 2001, Cancer research.
[19] R L Vessella,et al. Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS‐2 in prostate cancer , 1997, The Prostate.
[20] S. Ritchie,et al. Transcription of the Human c-Src Promoter Is Dependent on Sp1, a Novel Pyrimidine Binding Factor SPy, and Can Be Inhibited by Triplex-forming Oligonucleotides* , 2000, The Journal of Biological Chemistry.
[21] B. Wold,et al. Phosphorothioate oligonucleotide-directed triple helix formation. , 1994, Biochemistry.
[22] D. Fujita,et al. Organization and analysis of the promoter region and 5' non-coding exons of the human c-src proto-oncogene. , 1993, Oncogene.
[23] B. Pettitt,et al. Binding of triple helix forming oligonucleotides to sites in gene promoters. , 1991, Biochemistry.
[24] C. Catapano,et al. Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells. , 2000, Cancer research.
[25] B. Aggarwal,et al. Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. , 1996, Cancer research.
[26] Winter Ta. Gene targeted agents: new opportunities for rational drug development. , 2000 .
[27] Y. Israel,et al. Inhibition of Gene Expression by Triple Helix Formation in Hepatoma Cells (*) , 1995, The Journal of Biological Chemistry.
[28] D. Praseuth,et al. Triple helix formation and the antigene strategy for sequence-specific control of gene expression. , 1999, Biochimica et biophysica acta.
[29] A. Seth,et al. The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated. , 1990, Oncogene.
[30] G. Mavrothalassitis,et al. Positive and negative factors regulate the transcription of the ETS2 gene via an oncogene-responsive-like unit within the ETS2 promoter region. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[31] Michael C. Ostrowski,et al. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2 , 1996, Molecular and cellular biology.
[32] M. White,et al. Targeted inhibition of transcription elongation in cells mediated by triplex-forming oligonucleotides. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[33] Lyuba Benimetskaya,et al. Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide , 1997, Nucleic Acids Res..
[34] P. Glazer,et al. Specific mutations induced by triplex-forming oligonucleotides in mice. , 2000, Science.
[35] D. Gilliland. The diverse role of the ETS family of transcription factors in cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] C. Giovannangeli,et al. Accessibility of nuclear DNA to triplex-forming oligonucleotides: the integrated HIV-1 provirus as a target. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[37] P. Glazer,et al. Mutagenesis in Mammalian Cells Induced by Triple Helix Formation and Transcription-Coupled Repair , 1996, Science.
[38] A. Firulli,et al. DNA triplexes and regulation of the c-myc gene. , 1994, Gene.
[39] B. Wasylyk,et al. Reversion of Ras transformed cells by Ets transdominant mutants. , 1994, Oncogene.
[40] P. Glazer,et al. Triplex DNA: fundamentals, advances, and potential applications for gene therapy , 1997, Journal of Molecular Medicine.
[41] G. Mavrothalassitis,et al. Molecular and functional characterization of the promoter of ETS2, the human c-ets-2 gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[42] I Lebedeva,et al. Antisense oligonucleotides: promise and reality. , 2001, Annual review of pharmacology and toxicology.
[43] G. Mavrothalassitis,et al. The human ETS-2 gene promoter: molecular dissection and nuclease hypersensitivity. , 1990, Oncogene.
[44] A. Seth,et al. c-ets-2 protooncogene has mitogenic and oncogenic activity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[45] C. Hauser,et al. Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites. , 1994, Oncogene.